全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Development of an IgG4-RD Responder Index

DOI: 10.1155/2012/259408

Full-Text   Cite this paper   Add to My Lib

Abstract:

IgG4-related disease (IgG4-RD) is a multiorgan inflammatory disease in which diverse organ manifestations are linked by common histopathological and immunohistochemical features. Prospective studies of IgG4-RD patients are required to clarify the natural history, long-term prognosis, and treatment approaches in this recently recognized condition. Patients with IgG4-RD have different organ manifestations and are followed by multiple specialties. Divergent approaches to the assessment of patients can complicate the interpretation of studies, emphasizing the critical need for validated outcome measures, particularly assessments of disease activity and response to treatment. We developed a prototype IgG4-RD Responder Index (IgG4-RD RI) based on the approach used in the development of the Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG). The IgG4-RD RI was refined by members of the International IgG4-RD Symposium Organizing Committee in a paper case exercise. The revised instrument was applied retrospectively to fifteen IgG4-RD patients at our institution. Those scores were compared to physician’s global assessment scale for the same visits. This paper describes the philosophy and goals of the IgG4-RD RI, the steps in the development of this instrument to date, and future plans for validation of this instrument as an outcome measure. 1. Introduction Measurement of disease activity is critical for longitudinal assessments in both observational studies and clinical trials. In the field of rheumatology, more than 250 assessment tools have been developed and validated to evaluate pathology, symptoms, function, and health status of patients with rheumatic diseases [1]. Such instruments should be compatible with regulatory requirements of the Food and Drug Administration (FDA) and generally require prospective studies for completion of the validation process [2]. IgG4-related disease (IgG4-RD) is an increasingly recognized immune-mediated disease that is characterized by a lymphoplasmacytic infiltrate enriched with IgG4-positive plasma cells and a distinctive storiform fibrosis of affected organs [3]. Commonly involved organs include the pancreas, biliary tree, orbits, salivary glands, and retroperitoneum, among many others. Organ involvement usually occurs in a metachronous but overlapping fashion. The serum IgG4 level is often but not always elevated [4]. Because of the novelty of IgG4-RD, little effort to date has been devoted to the development of outcome measures for this newly recognized condition. A disease responder index is a

References

[1]  P. P. Katz, “Introduction to special issue: Patient outcomes in rheumatology, 2011,” Arthritis Care & Research, vol. 63, supplment 11, pp. S1–S3, 2011.
[2]  R. A. Furie, M. A. Petri, D. J. Wallace et al., “Novel evidence-based systemic lupus erythematosus responder index,” Arthritis Care and Research, vol. 61, no. 9, pp. 1143–1151, 2009.
[3]  A. Khosroshahi and J. H. Stone, “A clinical overview of IgG4-related systemic disease,” Current Opinion in Rheumatology, vol. 23, no. 1, pp. 57–66, 2011.
[4]  T. Tabata, T. Kamisawa, K. Takuma et al., “Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease,” Internal Medicine, vol. 50, no. 2, pp. 69–75, 2011.
[5]  A. Khosroshahi and J. H. Stone, “Treatment approaches to IgG4-related systemic disease,” Current Opinion in Rheumatology, vol. 23, no. 1, pp. 67–71, 2011.
[6]  A. Khosroshahi, D. B. Bloch, V. Deshpande, and J. H. Stone, “Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1755–1762, 2010.
[7]  J. H. Stone, G. S. Hoffman, P. A. Merkel et al., “A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score,” Arthritis and Rheumatism, vol. 44, no. 4, pp. 912–920, 2001.
[8]  P. A. Merkel, D. D. Cuthbertson, B. Hellmich, et al., “Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 103–106, 2009.
[9]  W. Cheuk and J. K. C. Chan, “IgG4-related sclerosing disease a critical appraisal of an evolving clinicopathologic entity,” Advances in Anatomic Pathology, vol. 17, no. 5, pp. 303–332, 2010.
[10]  A. Khosroshahi, M. N. Carruthers, V. Deshpande, S. Unizony, D. B. Bloch, and J. H. Stone, “Rituximab for the treatment of IgG4-related disease: Lessons from 10 consecutive patients,” Medicine, vol. 91, no. 1, pp. 57–66, 2012.
[11]  P. Seo, R. A. Luqmani, O. Flossmann et al., “The future of damage assessment in vasculitis,” Journal of Rheumatology, vol. 34, no. 6, pp. 1357–1371, 2007.
[12]  J. H. Stone, A. Khosroshahi, V. Deshpande, et al., “IgG4-related disease: recommendations for the nomenclature of this condition and its individual organ system manifestations,” Arthritis & Rheumatism. Submitted.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133